Pharmacyte Biotech (PMCB)Director bought ~$16K

~$16K

Approx. value · 20K sh @ $0.7776

153K

Holds after · shares reported

Traded

Jan 5, 2026

Filed

Jan 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 1, 2025Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On December 1, 2025, PharmaCyte Biotech, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market.”
2. Jan 5, 2026 · this disclosureInsiderDirector purchased ~$16K of PMCB shares in the open market

What came next

1. Jan 5, 2026InsiderCEO purchased ~$23K of PMCB shares in the open market
2. Jan 6, 2026Insider · 2 peopleInsiders: 2 purchases (~$39K)
3. Jan 7, 2026Insider · 2 peopleInsiders: 2 purchases (~$50K)
4. Mar 30, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On March 30, 2026, PharmaCyte Biotech, Inc. (the “Company”) held its annual meeting of stockholders for the year ended April 30, 2026 (the “Annual Meeting”) via live webcast.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Pharmacyte Biotech

OQRO holds no insider, Congress, fund or contract record for Pharmacyte Biotech dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PMCB page.

Other recent filings by Jonathan Schechter, Director

• SEC Form 4 at Pharmacyte Biotech (PMCB)Jan 7, 2026
• SEC Form 4 at Pharmacyte Biotech (PMCB)Jan 7, 2026
• SEC Form 4 at Taoweave (TWAV)Nov 17, 2025
• SEC Form 4 at Taoweave (TWAV)Sep 17, 2025
• SEC Form 4 at Taoweave (TWAV)Sep 16, 2025

The full history of Jonathan Schechter, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Pharmacyte Biotech

• SEC Form 4Jan 7, 2026
• SEC Form 4Jan 7, 2026
• SEC Form 4Jan 7, 2026
• SEC Form 4Jan 7, 2026
• SEC Form 4Jan 7, 2026

Everything OQRO holds on this company is on its PMCB page.